MEDGm Review: Is It Legit?

MEDGm is a telehealth platform for weight loss, hair loss and sleep care. It is not a medical practice itself. Licensed providers from the OpenLoop Health network do the prescribing.

Here is how it goes. You fill in a medical questionnaire online. A U.S. licensed provider reviews your case in an online visit. You get a prescription only after that review. The medication ships to you, and refills continue on the same subscription.

The menu is all compounded. There is compounded semaglutide as a weekly injection or a tablet, and compounded tirzepatide as an injection. There is no brand-name option for weight loss. The provider may also switch you to a different drug or dose if that suits your case better.

Compounded means a pharmacy makes the drug to a prescription. MEDGm's terms say plainly that these drugs can differ from Ozempic, Wegovy, Mounjaro and Zepbound in form and instructions. To understand the drugs themselves, read our pages on semaglutide and tirzepatide.

Mostly yes. MEDGm is a real telehealth platform with a named provider network, OpenLoop Health, public prices and no FDA warning letter. The gaps are the pharmacy, which it does not name, and the LegitScript badge, which it does not show. Those keep it from a plain yes.

MEDGm says plainly that it is a platform, not a medical practice: "MEDGm, LLC serves as the patient-facing telehealth platform and is not itself a licensed medical practice."

The pharmacy is the open question. MEDGm names no pharmacy and does not say what type of pharmacy makes its drugs. So there is nothing to match against the FDA register. For a compounded program, where the pharmacy makes the drug itself, that matters.

The rest is clear. Each product page names the drug and its form, and the terms say the drugs are compounded.

Compounded semaglutide injections cost $299 a month on the monthly plan. The drug, the visit and the shipping are included, with no other fee.

The first month is cheaper with the code WELCOME120OFF, which takes $120 off. That makes the first month $179 for semaglutide injections. The tablets are $369 a month, or $249 for the first month. Compounded tirzepatide is $399 a month, or $279 for the first month. Semaglutide is the same price at any dose.

Longer plans cost less per month, but you pay up front. Semaglutide injections are $597 for 3 months, $1,134 for 6 months and $2,028 for 12 months. That is $199, $189 and $169 a month. Tirzepatide runs $897, $1,734 or $3,228, which is $299, $289 or $269 a month. The tablets run $957, $1,734 or $2,868, which is $319, $289 or $239 a month.

There is nothing on top. The membership, consultation, lab and shipping fees are each $0. MEDGm does not bill insurance. Three months at the monthly rate total $777, with no fees added.

That puts MEDGm at rank 15 of 15 in its group on month-to-month prices, where the median is $199 a month. For scale, a pharmacy pays $871.12 for a Wegovy 1.7 mg pen package, effective September 23, 2026. That is an acquisition cost, not what a patient pays.

The care is online, with a provider visit up front and messaging after. You get one-to-one support through the platform. For medical questions, the terms send you to your provider through secure messaging, or to in-person care.

Your provider decides which drug you get. The terms say "The decision to use compounded medications is guided by the medical judgment of the licensed provider, which is based on a telemedicine consultation and the patient's medical history." Labs carry no extra fee.

MEDGm does not state how fast a provider reviews your case. Ask before you pay if you need to start by a set date.

MEDGm has no FDA warning letter and no open flag on its record. Its record is clean. There is nothing against a pharmacy either, because none is named.

The safety question with a compounded program is the drug itself. A compounded GLP-1 is made by a pharmacy, and the FDA does not review it the way it reviews Wegovy or Zepbound. MEDGm's terms say these drugs "may differ in appearance, color, viscosity, packaging, concentration, excipients, and administration instructions" from the brand-name products.

For side effects, doses and who should not take these drugs, read our semaglutide and tirzepatide pages, which quote the FDA labels. Safety scores 8.75 out of 10, held back only by the missing LegitScript badge.

On the monthly plan you can cancel at any time, with no minimum term. The product pages say it in so many words: billed monthly, cancel anytime.

The refund rule is strict. You pay for the plan term up front, and that fee is not refunded. The one exception is if a provider finds you ineligible before your first shipment. Then you get a full refund of the current term.

So the trap is the prepaid plan. The $169 rate needs 12 months paid up front, and you do not get that money back if you stop. Start on the monthly plan until you know the drug suits you.

We found no patient testimonial on the MEDGm pages we read, so there are no quote cards on this page. The only voice on the site is the brand's own. This site collects no independent reviews of its own.

That leaves you with little to go on from other patients. Read the prices, the plan lengths and the refund rule above for what you will pay and what you sign. If you want to hear from other patients first, look for independent reviews before you prepay a longer plan.

Price transparency scores 10 at a 20% weight: every price and fee is on a product page, and each one held when we read it again. Cost and value scores 1 at a 15% weight: rank 15 of 15 on month-to-month prices. Traceability scores 5.8 at a 15% weight: no pharmacy named. Clinical care scores 8.25 at a 15% weight: a named provider network, no stated wait time.

Safety scores 8.75 at a 20% weight: no letter, no flag, but no LegitScript badge. Terms score 10 at a 10% weight: the monthly plan cancels anytime and the refund rule is stated. Availability scores 7.25 at a 5% weight: free shipping, but no state list.

Our fresh computation gives 7.4, a move of 0.1. That is under our 0.3 threshold, so the published 7.3 stands until a later crawl confirms it. Since our last check, availability rose from 6 to 7.25 after site pages changed. The weights are on our methodology page.